Levetiracetam: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Levetiracetam. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Asthenia | 15% |
| Somnolence | 15% |
| Vomiting | 15% |
| Nasopharyngitis | 15% |
| Headache | 14% |
| Infection | 13% |
| Fatigue | 11% |
| Aggression | 10% |
| Dizziness | 9% |
| Abdominal pain upper | 9% |
| Cough | 9% |
| Nasal congestion | 9% |
| Decreased appetite | 8% |
| Pain | 7% |
| Abnormal behavior | 7% |
| Irritability | 7% |
| Pharyngolaryngeal pain | 7% |
| Pharyngitis | 6% |
| Diarrhea | 6% |
| Lethargy | 6% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
1.1 Partial Onset Seizures Levetiracetam tablets USP are indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. Information describing the use of levetiracetam in pediatric patients less than 4 years of age as adjunctive therapy in the treatment of partial onset seizures is approved for UCB, Inc.'s levetiracetam tablets. However, due to UCB, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 1.2 Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy Levetiracetam tablets USP are indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. 1.3 Primary Generalized Tonic-Clonic Seizures Levetiracetam tablets USP are indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.